美股异动 | 再鼎医药涨逾7%，DLL3 ADC启动一线SCLC全球三期临床

智通财经

Sep 02

智通财经APP获悉，周三，再鼎医药(ZLAB.US)涨逾7%。消息面上，8月31日，再鼎医药在Clinicaltrials.gov网站上注册了ZL-1310+PD-L1抗体一线治疗ES-SCLC的全球三期临床试验。该全球三期临床拟入组530例一线ES-SCLC患者，预计2030年6月初步完成。

ZL-1310为一款靶向DLL3的ADC新药，采用宜联新一代ADC技术TMALIN构建，以TOPO1抑制剂作为payload，具有高效力、高清除率和高渗透性的作用特点。ZL-1310在小细胞肺癌PDX模型的临床前研究中显示出强效杀伤作用。

中信建投此前发布研报称，公司自主研发资产正逐步进入临床价值验证阶段，核心自研管线有望于年内迎来密集数据读出及关键研发进展。2026 年下半年重要催化剂包括：Zoci(ZL-1310，DLL3 ADC)一线小细胞肺癌(1L SCLC)联合治疗数据公布、1L SCLC 及肺外神经内分泌癌(ep NE C)注册性开发推进；ZL-1503(IL-13×IL-31Rα 双抗)首次人体数据公布等。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2664122038"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2664122038\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2664122038?lang=en_US&edition=fundamental","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","is_english":false,"pubTime":"2026-09-02 21:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664122038","market":"hk","top_or_hot":-1,"title":"美股异动 | 再鼎医药涨逾7%，DLL3 ADC启动一线SCLC全球三期临床","media":"智通财经","content":"<html><head></head><body><p style=\"text-align: left;\">智通财经APP获悉，周三，<a href=\"https://laohu8.com/S/ZLAB\">再鼎医药</a>(ZLAB.US)涨逾7%。消息面上，8月31日，<a href=\"https://laohu8.com/S/09688\">再鼎医药</a>在Clinicaltrials.gov网站上注册了ZL-1310+PD-L1抗体一线治疗ES-SCLC的全球三期临床试验。该全球三期临床拟入组530例一线ES-SCLC患者，预计2030年6月初步完成。</p><p style=\"text-align: left;\">ZL-1310为一款靶向DLL3的ADC新药，采用宜联新一代ADC技术TMALIN构建，以TOPO1抑制剂作为payload，具有高效力、高清除率和高渗透性的作用特点。ZL-1310在小细胞肺癌PDX模型的临床前研究中显示出强效杀伤作用。</p><p style=\"text-align: left;\"><a href=\"https://laohu8.com/S/601066\">中信建投</a>此前发布研报称，公司自主研发资产正逐步进入临床价值验证阶段，核心自研管线有望于年内迎来密集数据读出及关键研发进展。2026 年下半年重要催化剂包括：Zoci(ZL-1310，DLL3 ADC)一线小细胞肺癌(1L SCLC)联合治疗数据公布、1L SCLC 及肺外神经内分泌癌(ep NE C)注册性开发推进；ZL-1503(IL-13×IL-31Rα 双抗)首次人体数据公布等。</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/750d95aba52ba1a0fb8f66a19d19fb74\" data-align=\"center\" data-image-type=\"kline\" tg-width=\"560\" tg-height=\"240\"/><span></span></p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美股异动 | 再鼎医药涨逾7%，DLL3 ADC启动一线SCLC全球三期临床</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美股异动 | 再鼎医药涨逾7%，DLL3 ADC启动一线SCLC全球三期临床\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-09-02 21:58 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1491227.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，周三，再鼎医药(ZLAB.US)涨逾7%。消息面上，8月31日，再鼎医药在Clinicaltrials.gov网站上注册了ZL-1310+PD-L1抗体一线治疗ES-SCLC的全球三期临床试验。该全球三期临床拟入组530例一线ES-SCLC患者，预计2030年6月初步完成。ZL-1310为一款靶向DLL3的ADC新药，采用宜联新一代ADC技术TMALIN构建，以TOPO1抑制剂...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1491227.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1491227.html","article_id":"2664122038","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664122038","pubTimestamp":1788357538,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"消息面上，8月31日，$再鼎医药$在Clinicaltrials.gov网站上注册了ZL-1310+PD-L1抗体一线治疗ES-SCLC的全球三期临床试验。该全球三期临床拟入组530例一线ES-SCLC患者，预计2030年6月初步完成。ZL-1310为一款靶向DLL3的ADC新药，采用宜联新一代ADC技术TMALIN构建，以TOPO1抑制剂作为payload，具有高效力、高清除率和高渗透性的作用特点。ZL-1310在小细胞肺癌PDX模型的临床前研究中显示出强效杀伤作用。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK4548":"巴美列捷福持仓","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4139":"生物科技","09688":"再鼎医药","BK4531":"中概回港概念","BK1574":"生物医药B类股","BK4588":"碎股","ZLAB":"再鼎医药","BK1588":"回港中概股","BK4526":"热门中概股"},"translate_title":"US Stocks in Focus | Zai Lab (ZLAB.US) Rises Over 8% as DLL3 ADC Launches Global Phase III Clinical Trial for First-Line SCLC","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/a04513a7a95d1c3ace7187623d8a9c5f","symbols_score_info":{"09688":1.5,"ZLAB":1.5},"content_text":"智通财经APP获悉，周三，再鼎医药(ZLAB.US)涨逾7%。消息面上，8月31日，再鼎医药在Clinicaltrials.gov网站上注册了ZL-1310+PD-L1抗体一线治疗ES-SCLC的全球三期临床试验。该全球三期临床拟入组530例一线ES-SCLC患者，预计2030年6月初步完成。ZL-1310为一款靶向DLL3的ADC新药，采用宜联新一代ADC技术TMALIN构建，以TOPO1抑制剂作为payload，具有高效力、高清除率和高渗透性的作用特点。ZL-1310在小细胞肺癌PDX模型的临床前研究中显示出强效杀伤作用。中信建投此前发布研报称，公司自主研发资产正逐步进入临床价值验证阶段，核心自研管线有望于年内迎来密集数据读出及关键研发进展。2026 年下半年重要催化剂包括：Zoci(ZL-1310，DLL3 ADC)一线小细胞肺癌(1L SCLC)联合治疗数据公布、1L SCLC 及肺外神经内分泌癌(ep NE C)注册性开发推进；ZL-1503(IL-13×IL-31Rα 双抗)首次人体数据公布等。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}